Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Kymera Therapeutics, Inc. (KYMR) reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of$13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due ...